I think this prospecting will create a problem though. If big pharma increasingly prefer to purchase startup biotech companies that have an asset at whatever ph

I think this prospecting will create a problem though. If big pharma increasingly prefer to purchase startup biotech companies that have an asset at whatever phase the pharma is looking for, then the only people developing new drugs will be small startups. It reduces the opportunity for assets built for one target to be worked up in another area (e.g. an autoimmune drug to be tried in models of ALS). It also discourages non-risky scientists, as the jobs will increasingly be in volatile companies that leave you wondering if your company card will work when you check into a hotel at a conference.